Treatment rationale and design of a phase III study of Afatinib or CHemotherapy In patients with non-smaLL-cell lung cancer harboring sensitizing uncommon Epidermal growth factor receptor mutationS (ACHILLES/TORG1834)

  • Satoru Miura, Takeharu Yamanaka, Terufumi Kato, Satoshi Ikeda, Hidehito Horinouchi, Eiki Ichihara, Masaki Kanazu, Yuichi Takiguchi, Kentaro Tanaka, Yasuhiro Goto, Masafumi Sata, Koichi Hagiwara, Hiroaki Okamoto, Hiroshi Tanaka
  • Clinical Lung Cancer, May 2020, Elsevier
  • DOI: 10.1016/j.cllc.2020.05.011

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/j.cllc.2020.05.011

The following have contributed to this page: Satoshi Ikeda